Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2)

Yukari Tsubata, Kana Watanabe, Ryota Saito, Atsushi Nakamura, Hiroshige Yoshioka, Mami Morita, Ryoichi Honda, Nobuhiro Kanaji, Satoshi Oizumi, Daisuke Jingu, Taku Nakagawa, Kensuke Nakazawa, Atsuto Mouri, Susumu Takeuchi, Naoki Furuya, Yuki Akazawa, Kiyotaka Miura, Eiki Ichihara, Makoto Maemondo, Satoshi MoritaKunihiko Kobayashi, Takeshi Isobe

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original publication, the name of ninth author was mistakenly published as: Satoshi Ohizumi. The correct name is: Satoshi Oizumi as given in this Correction.

Original languageEnglish
Pages (from-to)823-824
Number of pages2
JournalInternational Journal of Clinical Oncology
Volume27
Issue number4
DOIs
Publication statusPublished - Apr 2022
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2)'. Together they form a unique fingerprint.

Cite this